Septerna (NASDAQ:SEPN) Stock Price Up 6.4% – Here’s What Happened

Shares of Septerna, Inc. (NASDAQ:SEPN) shot up 6.4% during trading on Tuesday . The stock traded as high as $23.10 and last traded at $23.07. 84,226 shares were traded during trading, a decline of 60% from the average session volume of 211,519 shares. The stock had previously closed at $21.69.

Wall Street Analyst Weigh In

SEPN has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target on the stock. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, Wells Fargo & Company began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 target price on the stock.

Septerna Stock Performance

Insider Buying and Selling

In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.